Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Increase in Short Interest

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 274,891 shares, a growth of 23.8% from the January 15th total of 222,054 shares. Based on an average daily trading volume, of 41,454 shares, the short-interest ratio is presently 6.6 days. Approximately 4.9% of the shares of the company are short sold. Approximately 4.9% of the shares of the company are short sold. Based on an average daily trading volume, of 41,454 shares, the short-interest ratio is presently 6.6 days.

Armata Pharmaceuticals Trading Down 1.1%

ARMP traded down $0.09 during midday trading on Monday, reaching $8.15. The company’s stock had a trading volume of 25,317 shares, compared to its average volume of 40,359. Armata Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $16.34. The stock’s 50-day moving average is $6.60 and its 200-day moving average is $4.97. The firm has a market capitalization of $296.74 million, a price-to-earnings ratio of -5.03 and a beta of 1.42.

Analysts Set New Price Targets

Separately, Jones Trading started coverage on Armata Pharmaceuticals in a research report on Monday, January 5th. They set a “buy” rating and a $15.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.00.

Hedge Funds Weigh In On Armata Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARMP. Geode Capital Management LLC lifted its stake in Armata Pharmaceuticals by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after acquiring an additional 5,342 shares during the period. SeaCrest Wealth Management LLC raised its holdings in shares of Armata Pharmaceuticals by 17.3% during the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after purchasing an additional 6,034 shares during the last quarter. State Street Corp lifted its position in Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after purchasing an additional 10,500 shares during the period. Jane Street Group LLC bought a new position in Armata Pharmaceuticals during the fourth quarter valued at approximately $108,000. Finally, Renaissance Technologies LLC boosted its holdings in Armata Pharmaceuticals by 65.9% in the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after purchasing an additional 27,200 shares during the last quarter. 3.57% of the stock is owned by institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.